Introduction {#s1}
============

Breast cancer is the most common malignancy among women, accounting for nearly 1 in 3 cancers diagnosed and the second leading cause of cancer death among women in the United States [@pone.0070044-Ferlay1]. Survival rates are highly correlated with the extent of the disease at diagnosis whereas early stage disease confers superior survival rates. The majority of patients with advanced breast cancer eventually develop bone metastases. Breast cancer has a particular propensity for the bone; likewise, it has been previously demonstrated that the relationship between cancer cells and the bone microenvironment is mediated by a reciprocal interaction between cancer cells and normal bone cells [@pone.0070044-Coleman1]--[@pone.0070044-VanderPluijm1]. Due to their beneficial effects on bone turnover, bisphosphonates have been evaluated for the prevention and treatment of bone metastases in women with breast cancer [@pone.0070044-Gallo1]--[@pone.0070044-Pavlakis1]. Two large population-based cohort studies demonstrated a significant reduction in the incidence of breast cancer in women who were treated with BP for non-cancer indications for more than a year [@pone.0070044-Rennert1]--[@pone.0070044-Chlebowski1]. Both pre-clinical and clinical evidence indicate that BP exhibit anti-metastatic and anti-tumor properties, including the inhibition of angiogenesis, and a unique effect in the bony niche -- inhibition of cancer cell invasion and adhesion and the induction of apoptosis [@pone.0070044-Daubine1]--[@pone.0070044-Ottewell1]. The role of BP in addition to standard adjuvant treatment has been evaluated in several studies, yielding inconsistent evidence regarding the antitumor effect of BP [@pone.0070044-Delmas1]--[@pone.0070044-Mbus1].

In view of the conflicting data from randomized clinical trials, we performed a systematic review of the literature and a meta-analysis of all randomized trials to evaluate the impact of BP administration on survival in patients with early breast cancer in the adjuvant setting.

Methods {#s2}
=======

Data Sources {#s2a}
------------

We searched the Cochrane Central Register of Controlled Trials, published in The Cochrane Library, PubMed (1966 to 4.2012); EMBASE (1974 to 7.2012); LILACS (1982 to 7.2012); the database of clinical trials in non-metastatic breast cancer; conference proceedings of the American Society of Clinical Oncology (1995--7.2012), San Antonio Breast Cancer Symposium (1995--2012), proceedings of the European Society of Medical Oncology (ESMO); and databases of ongoing and unpublished trials: <http://www.clinicaltrials.gov> and ,<http://www.clinicaltrials.nci.nih.gov>. The terms (early OR adjuvant) AND (breast OR mammary) AND (tumor OR malign\* OR carcinoma\* OR cancer) AND (biphosphonates OR bisphosphonates OR clodronate OR pamidronate OR zoledronic acid OR ibandronate) were cross-searched. We scanned references of all included trials and reviews identified for additional studies.

Study Selection {#s2b}
---------------

We included randomized controlled trials that compared BP adjuvant therapy in addition to the standard therapy (cytotoxic or hormonal) with placebo in patients with early breast cancer in the adjuvant setting. We included trials regardless of publication status, date of publication, and language. Two authors (IBA and LV) independently inspected each reference title identified by the search and applied the inclusion criteria.

Data Extraction and Quality Assessment {#s2c}
--------------------------------------

Trials that fulfilled the inclusion criteria were assessed for methodological quality by two authors (IBA and LV). Information about randomization and allocation concealment, blinding, sample size, exclusions after randomization, and the length of follow-up were recorded [@pone.0070044-Higgins1]. The same two authors independently extracted the data from publications of included trials. The data extraction was discussed, decisions were documented, and, if necessary, the authors of the trials were contacted for clarification. Authors of included trials were contacted for all data relevant to the primary and secondary outcomes (survival and safety data) of this study and quality variables. In case of several publications for the same trial, the most updated one was extracted. Safety outcomes were pooled from the most updated publication of every trial.

Outcome Measures {#s2d}
----------------

The primary outcome was overall survival, which was defined as time from randomization to death. Secondary outcomes were disease-free survival (defined as the time from randomization to earliest occurrence of relapse or death from any cause), and toxicity (defined as grade 3 or 4 hematological and nonhematological adverse events).

Data Synthesis and Statistical Analysis {#s2e}
---------------------------------------

Hazard ratios (HRs) and variances for time-to-event outcomes were estimated as described by Parmar et al. [@pone.0070044-Mantel1] and pooled according to inverse of variance method (Review Manager \[RevMan\], version 5.1(Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). A HR less than 1.0 was in favor of bisphosphonate therapy. Relative risks (RRs) and 95% confidence intervals (CIs) for dichotomous data were estimated using the Mantel -- Haenszel method [@pone.0070044-Mantel1]. We used a fixed effect model. In case of performing a sensitivity analysis for the primary outcomes we repeated the above analysis using a random effects model (the DerSimonian and Laird method) [@pone.0070044-DerSimonian1]. Since the Mantel-Haenszel odds ratio method using a 0.5 zero-cell correction were shown to be biased when events are rare, we therefore performed for rare events as osteonecrosis of the jaw (ONJ) a sensitivity analysis by using Peto method [@pone.0070044-Sweeting1]. We assessed heterogeneity of trial results by the chi test of heterogeneity and the *I* ^2^ statistic of inconsistency. Statistically significant heterogeneity was defined as *P* less than .1 or an *I* ^2^ statistic greater than 50% [@pone.0070044-DerSimonian1]. In case of a significant heterogeneity (*I* ^2^\>50%) we used a random-effects model. Potential sources of heterogeneity were explored through stratifying by type of induction therapy (use of chemotherapy and endocrine therapy, endocrine therapy only, menopausal status), bisphosphonate\'s schedule and type of BP, allocation concealment, blinding, and size of studies. All statistical tests were two-sided.

We explored potential ground of heterogeneity through meta-regression, assessing the effect of percentage of patients receiving chemotherapy in addition to endocrine therapy in each study on the effect estimates for the primary outcome. Meta-regression was performed on the HR (Comprehensive Meta Analysis, version 2.2; BioStat, Englewood, NJ). The regression slope with its SE and significance of the model are reported.

Results {#s3}
=======

The literature search identified 490 trials up until 7.2012, of which 96 were considered potentially relevant. Additional trials were identified by searching conference proceedings and electronic resources of ongoing trials. [Figure 1](#pone-0070044-g001){ref-type="fig"} illustrates the process of study selection. Thirteen trials were designed to evaluate the effect of bisphosphonates on survival and fulfilled the inclusion criteria for published studies ([@pone.0070044-Delmas1]--[@pone.0070044-Mbus1]; including safety reports) including two recently published abstracts of large scale randomized controlled trials [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1].

![Randomized controlled trials search and selection.](pone.0070044.g001){#pone-0070044-g001}

Studies\' characteristics {#s3a}
-------------------------

A total of 15,762 patients were randomly assigned in the thirteen trials included in this meta-analysis. Nevertheless, in 3 studies disease free survival has been the primary endpoint with no report of overall survival data [@pone.0070044-Coleman2], [@pone.0070044-Eidtmann1]--[@pone.0070044-deBoer1], [@pone.0070044-Brufsky1]--[@pone.0070044-Brufsky2].

Trial Design {#s3b}
------------

In six trials [@pone.0070044-Coleman2]--[@pone.0070044-Eidtmann1], [@pone.0070044-Gnant1], [@pone.0070044-Coleman3], [@pone.0070044-Brufsky1], patients were randomly assigned to zoledronic acid in addition to standard- of-care therapy. Four trials used clodronate, [@pone.0070044-Saarto1]--[@pone.0070044-Powles1], [@pone.0070044-Diel1], [@pone.0070044-Paterson1], one trial used pamidronate [@pone.0070044-Kristensen1] and one risedronate [@pone.0070044-Delmas1] and one ibandronate [@pone.0070044-Mbus1]; the schedule varied as reflected in [Table 1](#pone-0070044-t001){ref-type="table"}.

10.1371/journal.pone.0070044.t001

###### Included studies\' characteristics.

![](pone.0070044.t001){#pone-0070044-t001-1}

  First Author, Year, Publication status                          BP, Schedule                         Duration of Treatment   Number of Patients BP/Placebo (or delayed)   Follow Up (median, moths)   Menopausal Status (% - post)   Adjuvant Chemotherapy (%, mean)   Adjuvant Endocrine Treatment
  ---------------------------------------- ---------------------------------------------------------- ----------------------- -------------------------------------------- --------------------------- ------------------------------ --------------------------------- ------------------------------
  Delmas, 1997                                                   PO Risedronate                                 2 y                              27/26                                36 m                          100                              100                          Tamoxifen
  Published PR                                           30 mg/d for 2 wk then 10 w off                                                                                                                                                                                 
  Saarto, 2004                                                   PO Clodronate                                  3 y                             139/143                               120 m                         47.7                             54                           Tamoxifen
  Published PR                                                     1600 mg/d                                                                                                                                                                                            
  Powels, 2006                                                   PO Clodronate                                  2 y                             530/539                               66 m                           50                              74                               NS
  Published PR                                                     1600 mg/d                                                                                                                                                                                            
  Diel,                                                          PO Clodronate                                  2 y                             157/145                               103 m                         62.5                            42.1                          Tamoxifen
  2008                                                             1600 mg/d                                                                                                                                                                                            
  Published PR                                                                                                                                                                                                                                                          
  Kristensen, 2008                                               PO Pamidronate                                 4 y                             460/493                               120 m                          33                              100                              NS
  Published PR                                                       150bid                                                                                                                                                                                             
  Brufsky,                                  Upfront IV zolendronic acid vs. Delayed zolendronic acid            5 y                             300/300                               61 m                          100                              47                           Letrozole
  Z-FAST, 2011                                                      4 mg q6m                                                                                                                                                                                            
  Published PR                                                                                                                                                                                                                                                          
  Coleman EZO-FAST, 2009                    Upfront IV zolendronic acid vs. Delayed zolendronic acid            5 y                             252/270                               36 m                          100                              53                           Letrozole
  Conference proceeding                                             4 mg q6m                                                                                                                                                                                            
  Leal,                                                       IV zolendronic acid                               1 y                              36/32                                96 m                          100                              90                           Tamoxifen
  2010???                                                           4 mg q3m                                                                                                                                                                                                     (AI -- 15%)
  Published PR                                                                                                                                                                                                                                                          
  Eidtmann, 2010,                           Upfront IV zolendronic acid vs. Delayed zolendronic acid            5 y                             532/533                               60 m                          100                              54                           Letrozole
  ZO-FAST                                                           4 mg q6m                                                                                                                                                                                            
  Published PR                                                                                                                                                                                                                                                          
  \+ update from SABCS 2011                                                                                                                                                                                                                                             
  Gnant, ABCSG12, 2011                                        IV zolendronic acid                               3 y                             899/904                               84 m                           0                               5.5                          Tamoxifen
  Published PR                                                      4 mg q6m                                                                                                                                                                                                     Anastrazole
  \+ update from SABCS 2011                                                                                                                                                                                                                                                     GnRH\* agonist
  Coleman, AZURE, 2011                                        IV zolendronic acid                               5 y                            1680/1680                              59 m                           55                              96                               NS
  Published PR                                                      4 mg q6m                                                                                                                                                                                            
  NSABP B34, 2012                                                PO Clondronate                                 3 y                            1662/1661                              101 m                          64                              68                               NS
                                                                   1600 mg/d                                                                                                                                                                                            
  GAIN,                                                          PO Ibandronate                                 2 y                             1996/998                              39 m                           52                              100                              NS
  2011, Conference proceeding                                       50 mg/d                                                                                                                                                                                             

PO -- Per os (oral); IV - intravenous; PR -- peer review; NS- not specified; GnRH -- Gonadotropin Releasing Hormone AI -- Aromatase inhibitor.

Quality of Trials {#s3c}
-----------------

Allocation concealment was reported as adequate in five trials [@pone.0070044-Powles1], [@pone.0070044-Gnant1], [@pone.0070044-Coleman3], [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1] and was not reported in the other eight trials. Few of the trials have been open-labeled. The quality assessment of the included trials has been performed according to the Cochrane risk of bias tool, as described in detail in [Table S1](#pone.0070044.s003){ref-type="supplementary-material"}. We appraised the rate of patients lost to follow up and in the majority of the studies the rate was \<10%. In three trials the rate was higher (Range -- 17--42%; [@pone.0070044-Leal1]--[@pone.0070044-Eidtmann1], [@pone.0070044-Paterson1]).

Overall Survival {#s3d}
----------------

Ten trials (13,571 patients) were eligible for the meta-analysis of overall survival [@pone.0070044-Delmas1]--[@pone.0070044-Diel1], [@pone.0070044-Leal1], [@pone.0070044-Gnant1], [@pone.0070044-Coleman3], [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1]. The numbers of randomly assigned and analyzed patients in each included trial are described in [Table 1](#pone-0070044-t001){ref-type="table"}. Patients who were treated with BP therapy had no statistically significant different overall survival than patients in the control group (HR of death = 0.89, 95% CI = 0.79 to 1.01; *I^2^* of heterogeneity −43%, random effect model) ([Figure 2a](#pone-0070044-g002){ref-type="fig"}). Sensitivity analysis of two trials that had short duration of follow up [@pone.0070044-Delmas1], [@pone.0070044-Leal1] demonstrated that HR remained robust lacking these trials (HR of death = 0.89, 95% CI = 0.77 to 1.01, compared with 0.89, 0.79--1.01), presented in [Figure S1](#pone.0070044.s002){ref-type="supplementary-material"}). The funnel plot of the primary outcome did not support a publication bias.

![Forest plot of hazard ratios (HRs) comparing (A) overall survival or (B) disease-free survial (DFS) for patients who received BP in addition to standard therapy vs. those who received standard therapy only.\
Hazard ratios for each trail are represented by the **squares**, the size of the square represents the weight of the trial in the meta-analysis, and the **horizontal line** crossing the square represents the 95% confidence interval (CI). The **diamonds** represent the estimated overall effect based on the meta-analysis random effect of all trials.](pone.0070044.g002){#pone-0070044-g002}

Disease Free Survival {#s3e}
---------------------

Nine trials (12,167 patients) were eligible for the meta-analysis of DFS [@pone.0070044-Saarto1], [@pone.0070044-Coleman2]--[@pone.0070044-Eidtmann1], [@pone.0070044-Gnant1], [@pone.0070044-Coleman3], [@pone.0070044-Brufsky1], [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1]. The numbers of randomly assigned and analyzed patients in each included trial are described in [Table 1](#pone-0070044-t001){ref-type="table"}. Patients who were treated with BPtherapy had no statistically significant better DFS than patients in the control group (HR of death = 0.95, 95% CI = 0.81 to 1.12; *I^2^* of heterogeneity −61%, random effect model) ([Figure 2b](#pone-0070044-g002){ref-type="fig"}). The funnel plot of the primary outcome did not support a publication bias.

Subgroup analysis according to menopausal status {#s3f}
------------------------------------------------

Six trials reported the DFS outcome stratified by menopausal status [@pone.0070044-Coleman2]--[@pone.0070044-Eidtmann1], [@pone.0070044-Coleman3], [@pone.0070044-Brufsky1], [@pone.0070044-Mbus1]. Postmenopausal patients who were treated with BP therapy had statistically significant better DFS than patients in the control group (HR of death = 0.81, 95% CI = 0.69 to 0.95; *I^2^* of heterogeneity −34%, fixed effect model) ([Figure 3](#pone-0070044-g003){ref-type="fig"}). Meta-analysis for overall survival stratified by postmenopausal status was feasible for two trials only, and indicated a favorable outcome for the intervention arm (HR of death = 0.74, 95% CI = 0.57 to 0.98).

![Forest plot of hazard ratios comparing disease-free survival for most-menopausal patients who received BP in addition to standard therapy vs. those who received standard therapy only.\
Hazard ratios for each trail are represented by the **squares**, the size of the square represents the weight of the trial in the meta-analysis, and the **horizontal line** crossing the square represents the 95% confidence interval (CI). The **diamonds** represent the estimated overall effect based on the meta-analysis random effect of all trials.](pone.0070044.g003){#pone-0070044-g003}

Interaction with potential confounders {#s3g}
--------------------------------------

In meta-regression ([Figure 4](#pone-0070044-g004){ref-type="fig"}), chemotherapy was negatively associated with HR of overall survival (coefficient, −0.23; standard error, 0.144).

![Meta regression of hazard ratios of overall survival in individual studies assessing the effect of percentage of patients receiving chemotherapy in addition to endocrine therapy.](pone.0070044.g004){#pone-0070044-g004}

Adverse Events {#s3h}
--------------

The rate of grade 3 or 4 adverse events was reported in thirteen trials [@pone.0070044-Saarto1]--[@pone.0070044-Kristensen1], [@pone.0070044-Coleman2], [@pone.0070044-Eidtmann1], [@pone.0070044-Gnant1], [@pone.0070044-Coleman4]--[@pone.0070044-Brufsky1], [@pone.0070044-Paterson1], [@pone.0070044-Lester2]--[@pone.0070044-VanPoznak1], including three studies [@pone.0070044-Lester2]--[@pone.0070044-VanPoznak1] that evaluated BP for reducing skeletal events without survival assessment, as depicted in [Table 2](#pone-0070044-t002){ref-type="table"}. Bisphosphonate therapy resulted in a lower rate of bone fractures in the intervention arm (RR = 0.59, 95% CI = 0.42 to 0.83). The rate of osteonecrosis of the jaw (ONJ) was higher in the BP arm than in the control arm (RR = 7.53 95% CI = 2.91 to 19.50). To note, that RR was similar by using either the Mantel-Haenszel or Peto method. Pyrexia was also significantly higher in the BP arm (RR = 3.36, 95% CI = 2.61 to 4.32). The incidence of all constitutional grade 3 to 4 adverse events was not statistically significantly affected by BP therapy compared to control as depicted in [Table 2](#pone-0070044-t002){ref-type="table"}.

10.1371/journal.pone.0070044.t002

###### Relative risks (RRs) of grade 3--4 adverse events for patients who received BP in addition to standard therapy *vs* those who received standard therapy only.

![](pone.0070044.t002){#pone-0070044-t002-2}

  ------------- ----------------------
  ONJ            7.53 \[2.91, 19.50\]
  Fractures      0.59 \[0.42, 0.83\]
  Arthralgia     0.98 \[0.76, 1.26\]
  Vomiting       1.14 \[0.82, 1.58\]
  Pyrexia        3.36 \[2.61, 4.32\]
  Hot flushes    0.95 \[0.86, 1.05\]
  Fatigue        0.83 \[0.61, 1.11\]
  Bone pain      1.35 \[0.98, 1.87\]
  ------------- ----------------------

Discussion {#s4}
==========

The results of our meta-analysis demonstrate a positive effect for BP on survival outcomes when administered in the adjuvant setting, only in post-menopausal patients with breast cancer. Meta-regression appraised the effect of confounders such as chemotherapy on the interaction between BP use and overall survival, and showed a negative association between chemotherapy use and the effect of BP on survival.

The primary endpoint of many BP trials in the setting of early breast cancer was a reduction in skeletal related events, while survival had not been an integral endpoint of the study. We attempted to avoid publication bias by searching for and including in our meta-analysis conference proceedings, databases of ongoing trials, and unpublished data, and indeed in the recent San-Antonio Breast Cancer Symposium (2011) two large scale trials [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1], have been primarily presented (one of which has been fully published later on) and were included in our meta-analysis.

Bisphosphonates have been proven to display high affinity for bone and to inhibit bone resorption by osteoclasts [@pone.0070044-Fisher1]--[@pone.0070044-Rodan1]. Newer generation, nitrogen-containing bisphosphonates, such as alendronate, risedronate, pamidronate, ibandronate, and zoledronic acid are considered an integral part of treatment to reduce the risk for skeletal related events in patients with bone metastases [@pone.0070044-Holen2]--[@pone.0070044-Bianchi1]. Many *in-vitro* studies have portrayed the effect of a variety of BP (both nitrogen containing and non-nitrogen bisphosphonates) to hinder tumor cell adhesion, invasion, proliferation and interplay with the bone microenvironment components such as matrix-metalloproteinases (MMPs) [@pone.0070044-NevilleWebbe1]--[@pone.0070044-Winter1]. Moreover in their well-recognized target, the osteoclast, BP interfere with signaling pathways (e.g. Rac and Ras) required for osteoclast function and survival [@pone.0070044-Hadji1]. Breast cancer cells have a unique predilection to metastasize to bone, whereas the microenvironment is highly receptive to metastatic tumor cells [@pone.0070044-VanderPluijm1].

Two large cohort studies evaluated breast cancer incidence in healthy postmenopausal women treated with bisphosphonates to prevent bone loss and showed a 29--32% statistically significant reduction in the incidence of invasive breast cancer, lending credence for a potential chemo- preventive effect for BP [@pone.0070044-Rennert1]--[@pone.0070044-Chlebowski1]. The benefit was observed both in ER-positive and ER-negative tumors, implying that the mechanisms may be hormonally-independent and might involve pathways such as angiogenesis inhibition, modulation of the immune system or a direct effect on the bone microenvironment.

The biological rationale for the benefit of BP in post-menopausal patients lies in the natural estrogen deficiency at postmenopause which leads to increased osteoclast activity, resulting in decreased bone mineral density (BMD), yet is still considered hypothetical. Bisphosphonates have been shown to be effective in numerous studies in preventing cancer treatment-associated bone loss in postmenopausal women with early breast cancer [@pone.0070044-Hadji1]--[@pone.0070044-Lester1] mainly due to their effect on the highly activated osteoclasts. Of note, the increase in bone loss is 5-fold higher following treatment with aromatase inhibitors (AIs) than physiological bone loss observed in postmenopausal women with established osteoporosis in the absence of AI therapy, and further induce bone turnover than documented during tamoxifen use [@pone.0070044-Coleman5]--[@pone.0070044-Safra1]. A recent study by Cheung indicated that the effect of aromatase inhibitors (exemestane) on bone density may be underestimated and that exemestane increases cortical bone permeability thus predisposing the patient to loss of bone strength and non-vertebral fractures [@pone.0070044-Cheung1]--[@pone.0070044-Cauley1].

Moreover, *in vitro* studies have indicated there may be a synergistic effect between zoledronic acid and letrozole on breast cancer cell lines [@pone.0070044-NevilleWebbe2]. This has been the leading rationale for the design of the Z-FAST, ZO-FAST, E-ZO-FAST that evaluated zoledronic acid in combination with AI [@pone.0070044-Coleman2], [@pone.0070044-Eidtmann1], [@pone.0070044-Brufsky1]. Premenopausal patient who become pharmacologically-induced postmenopausal by Gonadotropin Relasing Hormone agonists (GnRHa) may benefit from the addition of bisphosphonates, since bone turnover is further enhanced in premenopausal women who undergo chemical ovarian suppression\' as indicated in the ABCSG-12 trial [@pone.0070044-Gnant1]. Meta-regression that assessed the effect of chemotherapy on the association between BP use and survival indicated that the use of chemotherapy may lessen the effect of BP on survival. This result may elucidate the lack of survival benefit in few of the included studies in which chemotherapy was administered in a major portion of the study population [@pone.0070044-Leal1], [@pone.0070044-Coleman3], [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1]. On the contrary, in the ABSCG-12 which demonstrated an impressive survival benefit for the addition of zoledronic acid, less than 5% of the patients received chemotherapy.

Meta-analysis of the adverse events as reported in the included studies revealed a significant increase in pyrexia as well as osteonecrosis of the jaw (ONJ). Nevertheless, the incidence of ONJ is extremely low (0.24%, according to a recent meta-analysis [@pone.0070044-Mauri1]) and is therefore still considered a non-frequent adverse effect of BP. Although oral bisphosphonates are often associated with gastrointestinal adverse effects while intravenous bisphosphonates have been associated with infusion rate-dependent effect on renal function, the incidence of these adverse events was not statistically significant in all of the studies. Adequate hydration, serum creatinine monitoring and dose reductions in patients with renal impairment prior to BP administration are mandatory in the oncology setting and may support the lack of renal toxicity in the studies.

Limitations {#s4a}
-----------

Several limitations of this analysis must be acknowledged. The study population varies between trials with regard to the risk of recurrence: whereas in few of the large-scale trials most patients had positive lymph nodes at diagnosis [@pone.0070044-Coleman3], [@pone.0070044-Paterson1]--[@pone.0070044-Mbus1], indicating an a-priori worse prognosis than for patients with N0 disease as in the ABCSG-12 trial. Chemotherapy administration differs among studies; in the AZURE trial almost all patients received chemotherapy, in few trials all patients received chemotherapy [@pone.0070044-Kristensen1], [@pone.0070044-Leal1], [@pone.0070044-Mbus1] and in several studies more than half of the patients received chemotherapy [@pone.0070044-Powles1], [@pone.0070044-Diel1]--[@pone.0070044-Coleman2], [@pone.0070044-Eidtmann1], [@pone.0070044-Brufsky1], [@pone.0070044-Paterson1]. On the contrary, in the ABSCG-12 less than 5% received chemotherapy, also reflecting the good prognosis of the included population. This heterogeneity prompted us to perform meta-regression which indeed demonstrated that chemotherapy administration correlates with a lack of effect to BP. It should be acknowledged that the result of the meta-regression may reflect more the higher risk group in which chemotherapy was used and less so the effect of chemotherapy itself; along with the known limitations of a meta-regression [@pone.0070044-Mantel1]. Although meta-analysis of the subgroup of post-menopausal patients was feasible due to a separate report on the outcome of this population, in some of the trials the study population was not stratified by menopausal status. Moreover, the trials differ by the specific BP that had been employed. Upon *in vitro* studies, zoledronic acid may exhibit more potent anti-cancer effect than other BP.

The schedule and duration of the intervention varies between studies and could account for the apparent discrepancy in survival. Pre-clinical studies have demonstrated the activation of T cells by bisphosphonate as their key anti-tumor effect which is paradoxically reduced with each subsequent administration of BP. Thus, frequent administration as in few of the trials may result in a reduced anti-tumor effect [@pone.0070044-Kunzmann1]--[@pone.0070044-vanderVliet1].

Implication for research {#s4b}
------------------------

As indicated by our results, the group of patients that tends to benefit the most from the addition of BP in the adjuvant setting is the post-menopausal population, especially those who are not treated with chemotherapy. In the era of tailored therapy, the use of molecular techniques enables to individualize prognostic and predictive genetic traits by the 21-gene recurrence score (RS) assay (Oncotype Dx) or a microarray of 70-gene expression profile (Mammaprint) identifies subsets of patients with estrogen receptor positive tumors, who are not treated with chemotherapy; it would therefore be of value to elucidate the role of BP in a randomized trial in this population. This design may define clearly the potential benefit of bisphosphonates while the use of chemotherapy would not hamper their potential anti-tumor effect.

Implications for practice {#s4c}
-------------------------

Our meta-analysis provides a reflection of the new mounting and highly significant data published in the last 3 years which shed new light on the results of a former published meta-analysis on this matter both regarding efficacy and safety of BP in early breast cancer [@pone.0070044-Mauri1]. In view of the lack of evidence for the effectiveness of BP on survival in patients treated with chemotherapy or in premenopausal patients, this treatment should be considered in addition to endocrine treatment only in a subset of postmenopausal patients who are not scheduled for chemotherapy or as part of a clinical trial. Furthermore, the protective effect of BP on bone loss associated with AIs in postmenopausal women with early breast cancer as demonstrated in former studies further rationalize adopting these agents in this population. The addition of BP to the armamentarium of adjuvant treatments for early breast cancer should be further delineated in large scale RCTs which may unravel the specific subgroup that may benefit from this intervention.

Supporting Information {#s5}
======================

###### 

**Checklist items according to PRISMA criteria.**

(DOC)

###### 

Click here for additional data file.

###### 

**Sensitivity analysis of survival according to median follow up duration.** Hazard ratios for each trial are represented by the **squares**, the size of the square represents the weight of the trial in the meta-analysis, and the **horizontal line** crossing the square represents the 95% confidence interval (CI). The **diamonds** represent the estimated overall effect based on the meta-analysis random effect of all trials.

(TIFF)

###### 

Click here for additional data file.

###### 

**Quality assessment of included studies according to Cochrane criteria.** Quality assessment: Low risk-adequate (central randomization; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered sealed opaque envelopes; other convincing) Unclear -- not reported.

(PDF)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**Salomon M. Stemmer is an editor of PLOS ONE. This does not alter the authors\' adherence to all the PLOS ONE policies on sharing data and materials.

[^2]: Conceived and designed the experiments: IBA LV SMS. Performed the experiments: IBA LV. Analyzed the data: IBA LV SR RY OS AS SMS. Contributed reagents/materials/analysis tools: IBA LV. Wrote the paper: IBA LV SMS.
